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SchizophreniaThe only certain thing in life is that it will one day end. This
absolute truth it becomes tragic if prematurely occur.
Schizophrenia is a devastating mental disorder that affects 1%
of the world population and often leads a deteriorating course and
premature mortality [1,2]. In people with schizophrenia, the
mortality rate may be two to three times higher as that of the
general population, corresponding to a 10–25 year reduction in life
expectancy [2–6]. Actually, neuroscientists have been trying to
identify risk factors for sudden death in individuals with schizo-
phrenia, but the knowledge is still limited. Well-known reasons for
these deaths are related to some events triggered by unnatural
causes such as suicides, accidents, violence, and substance abuse
[1–4,6,7]. At the same time, a substantial proportion of individuals
with schizophrenia die of natural causes, prematurely and sud-
denly [1,2,4]. Because of this important consideration, the phe-
nomenon of sudden cardiac death in this particular population has
received a special attention of the scientiﬁc community at least the
last twenty years. In patients with schizophrenia, cardiovascular
diseases are on average 40–50% of all natural deaths, and schizo-
phrenia individuals have been reported to be three times as likely
to experience sudden cardiac death [1,2,4,8]. Thus, it has been
established that people using antipsychotics may have important
cardiovascular adverse events (e.g., QT interval prolongation),
suggesting that this could lead to torsade the points or sudden
death [2,9–13]. In the same sequence, a signiﬁcant proportion of
studies have suggested that schizophrenia and/or antipsychotic
agents are also associated with metabolic impairment including
diabetes mellitus, increased triglyceride levels and weight gain, all
of them known to be related with increased cardiovascular risk
[2,4,9–11,13,14]. In addition, the prevalence of smoking related
mortality in people with schizophrenia is well documented and
the effects of it may be due by an increase in platelet adhesiveness
and release of catecholamines [2,15].x.doi.org/10.1016/j.slsci.2016.08.002
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eview under responsibility of Brazilian Association of Sleep.According to the studies to date, obstructive sleep apnea (OSA)
is the common type of sleep-disordered breathing that is often an
underappreciated co-existing illness among people with schizo-
phrenia [16,17]. Following this line of reasoning, OSA should be on
the list of risk factors for sudden cardiac death among people with
schizophrenia for a number of reasons. OSA is a multifactorial
sleep disorder that affects up to 30% of the population and, as
elegantly published in the Sleep Heart Health study, is associated
to an increased risk of cardiovascular mortality and morbidity
[18,19]. In addition to these points, OSA has a threefold greater risk
of all cause mortality and a higher cardiovascular mortality at 18-
year follow-up [20–22] and has been independently correlated
with speciﬁc cardiovascular repercussion such as hypertension
[23], ischemic stroke [24,25], myocardial ischemia [26,27], ar-
rhythmias and hence sudden cardiac death [28,29]. Considering
the psychiatric disorders, it must be carefully assessed that the
presence of OSA in people with schizophrenia may potentiate the
possible cardiovascular dysfunctions and even increase the risk of
sudden cardiac death in these individuals. As we know, after the
recent, elegant and elucidative article outlined by Naqvi and col-
leagues, is clearly known that sleep disturbances are commonly
seen in schizophrenia patients with 80% of hospitalized in-
dividuals with schizophrenia having some form of sleep disorder
[30,31]. Interestingly, although there are several prevalence stu-
dies evaluated in clinic populations, there is no population-based
study on the incidence of OSA in schizophrenia ﬁeld [for review
see [31]]. Based on these facts, it has been constantly determined
in medical literature that schizophrenia and OSA are very common
diseases with serious implications in terms of the impact on public
health. Unfortunately, both diseases have high mortality rates and
OSA people and schizophrenia patients are at increased risk of
sudden cardiac death in general. On this date, further progress
should be made in relation to medical management againstV. This is an open access article under the CC BY-NC-ND license
Editorial / Sleep Science 9 (2016) 57–5858sudden death in individuals with schizophrenia, once the problem
persists and is increasing. In our current understanding, one of the
reasons for changes in this scenario would be through the trans-
lational research, which was properly incorporated in the dic-
tionary of medical sciences, indicates the integration of the ad-
vancements in basic science with clinical trials, taking research
from the “bench-to-bedside” [32]. Despite the long road, it is time
to establish a taskforce to assess the state of art/knowledge re-
garding the precise association between the occurrence of sudden
cardiac death and OSA in people with schizophrenia, including
clinical directions, research projects, and educational and social
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